Search

Corvus Pharmaceuticals Inc

Geschlossen

15.03 2.18

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.3

Max

14.96

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.4M

-14M

EPS

-0.15

Angestellte

37

EBITDA

312K

-12M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+114.82% upside

Dividenden

By Acuity

Nächstes Ergebnis

6. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-29M

1.3B

Vorheriger Eröffnungskurs

12.85

Vorheriger Schlusskurs

15.03

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Juli 2026, 23:56 UTC

Correlated Moves

Skyworks Solutions Inc shares are higher in after-market trading, supported by positive sentiment in the semiconductor sector and strong earnings from major banks.

14. Juli 2026, 23:56 UTC

JD.Com Inc. shares advanced in after-market trading, supported by strong earnings from major banks and a positive market backdrop. The stock remains above its 20-day moving average.

14. Juli 2026, 23:56 UTC

ETF Constituents

The iShares China Large-Cap ETF is higher in after-market trading, supported by favorable USD/CNH exchange rate movements and contributions from JD.

14. Juli 2026, 23:56 UTC

Vanguard Total International Bond ETF remains roughly flat in after-market trading. Global equity indices are higher following lower-than-expected U.S. inflation data.

14. Juli 2026, 23:56 UTC

iShares National Muni Bond ETF remains roughly flat in after-market trading. Global equity indices are higher following lower-than-expected U.S. inflation data.

14. Juli 2026, 23:52 UTC

Verisk Analytics Inc shares are lower in after-market hours, with no specific news identified. The decline contrasts with positive sentiment from strong bank earnings.

14. Juli 2026, 23:52 UTC

South Korea's June unemployment rate improves to 2.7%, boosting market confidence amid global economic recovery.

14. Juli 2026, 23:52 UTC

Brazil's Central Bank to Release Key SELIC Rate Insights Amid Global Inflation Concerns on July 20, 2026.

14. Juli 2026, 23:52 UTC

U.S. Industrial Production Data Release on July 17, 2026, Expected to Show Modest Growth Amid Cautious Economic Sentiment and Global Market Volatility.

14. Juli 2026, 23:52 UTC

China's Q2 GDP Growth Rate Expected to Slow to 0.9% Amid Strong Export Surge and Cautious Consumer Sentiment

14. Juli 2026, 23:52 UTC

Japan's upcoming Exports YoY report on July 21, 2026, is generating cautious optimism among investors amid positive regional trends and strong Chinese export data.

14. Juli 2026, 23:52 UTC

Japan's Upcoming Balance of Trade Data on July 21, 2026, Sparks Cautious Investor Sentiment Amidst Persistent Trade Deficits and Global Commodity Price Fluctuations.

14. Juli 2026, 23:51 UTC

U.S. Inflation Drops More Than Expected, Boosting European Equity Futures Amid Geopolitical Tensions

14. Juli 2026, 23:51 UTC

U.S. inflation drops unexpectedly, boosting global equity markets despite mixed results in the U.S. and ongoing geopolitical tensions affecting oil prices.

14. Juli 2026, 23:51 UTC

Asian equity markets rise on strong Chinese trade data, while U.S. stock futures react to softer inflation and mixed earnings amid geopolitical tensions.

14. Juli 2026, 23:51 UTC

U.S. equity markets show mixed results as weaker-than-expected inflation data eases rate hike fears, while geopolitical tensions and strong bank earnings drive volatility.

14. Juli 2026, 23:46 UTC

ETF Constituents

iShares Core MSCI EAFE ETF declines in after-market hours, influenced by top holdings BHP and TM. Performance remains flat since Tuesday's close.

14. Juli 2026, 23:46 UTC

ETF Constituents

iShares Biotechnology ETF declines in after-hours trading, continuing a trend of lower daily closes amid declines from key holdings like EDIT and ADPT.

14. Juli 2026, 23:46 UTC

MercadoLibre Inc shares are higher in after-market hours, supported by strong bank earnings that eased interest rate concerns. No specific news was identified for the stock.

14. Juli 2026, 23:46 UTC

News

PayPal Holdings Inc. shares are lower in after-market trading despite expanding buy now, pay later options in the UK with a new Pay in 30 Days feature.

14. Juli 2026, 23:42 UTC

Japan's Machinery Orders Expected to Decline by -4.2% MoM Amid Geopolitical Tensions and Market Caution

14. Juli 2026, 23:42 UTC

China's Fixed Asset Investment Expected to Contract Further Amid Weak Economic Indicators and Cautious Market Sentiment

14. Juli 2026, 23:42 UTC

China's Industrial Production YoY data for June 2026, expected to rise to 4.6%, set for release on July 15 amid cautious optimism influenced by strong trade figures and geopolitical tensions.

14. Juli 2026, 23:42 UTC

China's Retail Sales Expected to Decline by 0.1% YoY Amid Mixed Economic Signals Ahead of July Release

14. Juli 2026, 23:42 UTC

China's Q2 2026 GDP Growth Rate Expected at 4.5%, Amid Mixed Economic Signals and Global Uncertainties

14. Juli 2026, 23:42 UTC

Bank of Canada's Monetary Policy Report on July 15, 2026, expected to maintain interest rates amid stable inflation and geopolitical tensions.

14. Juli 2026, 23:41 UTC

Event
News

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

14. Juli 2026, 23:41 UTC

Macro Event
Correlated Moves
Macro News

Crude oil prices have risen, reaching $79 per barrel amid U.S.-Iran tensions. The EUR/USD exchange rate is modestly higher since Monday's close.

14. Juli 2026, 23:41 UTC

Macro News
Macro Event
Correlated Moves

Bitcoin is rising as geopolitical tensions boost oil prices and soft U.S. inflation data eases rate hike fears. Ethereum's gains may further support Bitcoin's momentum.

14. Juli 2026, 23:36 UTC

Autodesk Inc shares advanced after-market, reaching a high of 0.78% since Tuesday's close, despite no specific news driving the movement.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

114.82% Vorteil

12-Monats-Prognose

Durchschnitt 31.6 USD  114.82%

Hoch 40 USD

Tief 27 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

5

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat